Want to see IMRX full AI Analyst Report?
IMRX Stock Chart & Stats
$5.56
-$0.24(-10.17%)
At close: 4:00 PM EST
$5.56
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$2.90 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)2.27M
Market Cap
$332.54M
Enterprise Value$3.84B
Total Cash (Recent Filing)$156.69M
Total Debt (Recent Filing)$3.73B
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding64,697,230
10 Day Avg. Volume1,793,269
30 Day Avg. Volume2,268,073
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-6.37
Enterprise Value/Market Cap11.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.34K
Enterprise Value/Ebitda-65.30
Forecast
1Y Price Target
$14.40Price Target Upside158.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Phase 2a Data And Phase 3 PathRobust Phase 2a results with a clear plan for a mid-2026 pivotal Phase 3 materially de-risks the lead program. Sustained clinical progress provides a durable pathway to regulatory proof-of-concept, supports potential partnerships, and drives long-term value beyond short-term market moves.
Proprietary AI-driven Discovery PlatformAn in-house computational biology and AI platform is a structural competitive advantage: it can accelerate candidate identification, lower per-program discovery costs, and enable pipeline breadth. Over months this supports sustained R&D productivity and potential non-dilutive collaborations.
Low Financial LeverageVery low debt reduces solvency and interest-rate risk, preserving financial flexibility while the company funds development. For a cash-burning clinical-stage biotech, limited leverage lessens bankruptcy risk and makes future capital raises and strategic deals easier to execute over the medium term.
Bears Say
No Meaningful Revenue; Persistent Net LossesThe absence of revenue and ongoing sizable net losses mean the firm’s long-term viability depends entirely on clinical success or new financing. Without commercial cash flow, margins are non-existent and shareholder returns remain negative until a product is approved and launched.
Negative Operating And Free Cash Flow; High BurnConsistently negative operating and free cash flow create ongoing funding needs and heighten dilution risk from equity raises. Even with some year-over-year improvement, the TTM deterioration signals volatile cash requirements that constrain strategic optionality over the coming 2–6 months.
Clinical Outcome And Safety UncertaintyPhase 2a efficacy is promising but cross-trial comparisons are non-definitive and notable Grade 3+ hematologic events exist. The pivotal Phase 3 outcome and safety tolerability will determine regulatory success and commercial uptake; until then program and revenue prospects remain uncertain.
Immuneering News
IMRX FAQ
What was Immuneering Corp. Class A’s price range in the past 12 months?
Immuneering Corp. Class A lowest stock price was $2.90 and its highest was $10.08 in the past 12 months.
What is Immuneering Corp. Class A’s market cap?
Immuneering Corp. Class A’s market cap is $332.54M.
When is Immuneering Corp. Class A’s upcoming earnings report date?
Immuneering Corp. Class A’s upcoming earnings report date is Aug 12, 2026 which is in 34 days.
How were Immuneering Corp. Class A’s earnings last quarter?
Immuneering Corp. Class A released its earnings results on May 15, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.252 by $0.042.
Is Immuneering Corp. Class A overvalued?
According to Wall Street analysts Immuneering Corp. Class A’s price is currently Undervalued.
Does Immuneering Corp. Class A pay dividends?
Immuneering Corp. Class A does not currently pay dividends.
What is Immuneering Corp. Class A’s EPS estimate?
Immuneering Corp. Class A’s EPS estimate is -0.27.
How many shares outstanding does Immuneering Corp. Class A have?
Immuneering Corp. Class A has 64,697,230 shares outstanding.
What happened to Immuneering Corp. Class A’s price movement after its last earnings report?
Immuneering Corp. Class A reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.252. Following the earnings report the stock price went up 0.389%.
Which hedge fund is a major shareholder of Immuneering Corp. Class A?
Currently, no hedge funds are holding shares in IMRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immuneering Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.40 (158.99% Upside)
$14.40 (158.99% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 181.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $36.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.92%
12-Months-Change
Fundamentals
Return on Equity
-0.11%
Trailing 12-Months
Asset Growth
323.84%
Trailing 12-Months
Company Description
Immuneering Corp. Class A
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
IMRX Stock 12 Month Forecast
Average Price Target
$14.40
▲(158.99% Upside)
Technical Analysis
Ownership Overview
9.38% Insiders
15.57% Mutual Funds
0.31% Other Institutional Investors
66.59% Public Companies and
Individual Investors